Table 1.
Characteristics of Patients Receiving Dalbavancin Between January 31, 2016 and January 31, 2021
| Characteristic | No. (%) |
|---|---|
| Age | |
| 30–44 y | 3 (7) |
| 45–65 y | 17 (40) |
| 66–75 y | 16 (38) |
| ≥76 y | 6 (14) |
| Sex, male | 42 (100) |
| Comorbidities | |
| Diabetes mellitus | 23 (55) |
| Liver disease | 13 (31) |
| Active substance use disorder | 6 (14) |
| Type of infection | |
| Osteomyelitis | 21 (50) |
| Skin and soft-tissue infection | 10 (24) |
| Endocarditis or bacteremia | 9 (21) |
| Septic arthritis | 2 (5) |
| Inpatient consultations | |
| Infectious diseases | 42 (100) |
| Podiatry | 19 (45) |
| Orthopedic surgery | 4 (10) |
| Interventional radiology | 3 (7) |
| Cardiothoracic surgery | 2 (5) |
| Vascular surgery | 2 (5) |
| General surgery | 2 (5) |
| Plastic surgery | 1 (2) |
| Microbiologic culture data | |
| Staphylococcus spp | 22 (52) |
| Polymicrobial | 13 (31) |
| Corynebacterium spp | 10 (24) |
| Streptococcus spp | 5 (12) |
| Empiric | 4 (10) |
| Indication for Dalbavancin | |
| Ineligible for outpatient parenteral antibiotic therapy | 21 (50) |
| Pharmacologic factors | 10 (24) |
| Ineligible for peripherally inserted central catheter | 6 (14) |
| Active substance use disorder | 6 (14) |
| Outcomes | |
| Clinical cure | 39 (93) |
| Readmission | 5 (12) |
| Hepatotoxicity | 5 (12) |
| Mortality | 2 (5) |